Klotho Neurosciences Finalizes Shareholder Vote on Reverse Split to Avoid Delisting, Proposes Significant Equity Plan Expansion
KLTO has more than doubled off its 52-week low of $0.114.
Summary
Klotho Neurosciences has filed its definitive proxy statement, setting the terms for a shareholder vote on a reverse stock split to maintain Nasdaq listing and a substantial increase in its equity incentive plan, which could lead to significant dilution.
Key Events · Corporate Governance and Compliance · KLTO
-
Reverse Stock Split Proposal
Shareholders will vote on a reverse stock split with a ratio between one-for-2 and one-for-50, aimed at increasing the per-share price to meet Nasdaq's $1.00 minimum bid requirement and avoid delisting.
-
Equity Incentive Plan Expansion
The company seeks to increase the shares available under its 2024 Equity Incentive Plan to 10,000,000, representing a potential dilution of approximately 13.3% of current outstanding shares, to attract and retain key personnel.
-
Special Meeting Scheduled
A virtual Special Meeting of Stockholders is scheduled for February 13, 2026, to vote on these critical proposals.
Analysis · KLTO · Life Sciences
This definitive proxy statement (DEF 14A) finalizes the terms for a special meeting of stockholders, following the preliminary proxy (PRE 14A) filed on January 12, 2026. The company is seeking approval for a reverse stock split, with a wide ratio range of one-for-2 to one-for-50, primarily to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. This is a critical measure to avoid potential delisting. Additionally, shareholders will vote on a substantial amendment to the 2024 Equity Incentive Plan, increasing the shares reserved for issuance to 10,000,000. This represents a significant potential dilution of approximately 13.3% of current outstanding shares, which could impact existing shareholder value. The necessity of these actions highlights the company's challenges in maintaining its listing and attracting talent, making this a very important filing for investors.
At the time of this filing, KLTO was trading at $0.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24M. The 52-week trading range was $0.11 to $3.91. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.